Lake Street Capital Issues Pessimistic Forecast for Ekso Bionics (NASDAQ:EKSO) Stock Price

Ekso Bionics (NASDAQ:EKSO) had its target price reduced by equities research analysts at Lake Street Capital from $2.50 to $2.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price objective points to a potential upside of 114.59% from the stock’s previous close.

A number of other research firms have also commented on EKSO. HC Wainwright lowered their price target on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday. StockNews.com began coverage on shares of Ekso Bionics in a research note on Saturday, October 26th. They set a “hold” rating for the company.

Ekso Bionics Stock Down 2.9 %

Shares of NASDAQ EKSO opened at $0.93 on Tuesday. The company has a 50 day simple moving average of $1.11 and a 200 day simple moving average of $1.15. The firm has a market cap of $16.94 million, a PE ratio of -0.96 and a beta of 1.45. Ekso Bionics has a 1 year low of $0.83 and a 1 year high of $3.13. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.42 and a quick ratio of 1.77.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. The firm had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. During the same period in the prior year, the company posted ($0.24) EPS. On average, research analysts forecast that Ekso Bionics will post -0.42 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC boosted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.